# US 2002/0173663 A1 · Aryloxyacetic acids for diabetes and lipid disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0173663 A1
- Document ID: US20020173663A1
- Status: Published application
- Kind: A1
- Application number: 09/932,834
- Filed: 2001-08-17
- Published: 2002-11-21
- Earliest claimed: 2000-02-18
- Assignees: Merck & Co., Inc.
- Inventors: Kun Liu; Libo Xu; A. Brian Jones
- Web page: https://patentgrep.com/patent/US20020173663A1

## CPC

- C07D 261/20: condensed with carbocyclic rings or ring systems
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A class of aryloxyacetic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.

## Claims

### Claim 1

A compound having the formula I:
40
and pharmaceutically acceptable salts and prodrugs thereof, wherein
R1 and R2 are each independently selected from the group consisting of H, F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-3 halogen atoms; or optionally R1 and R2 together form a C3-6 cycloalkyl;
R3 and R4 are each independently selected from the group consisting of C1-C5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups may be linear or branched and are optionally substituted with 1-5 fluorine atoms;
X is N or CR;
Y is O, S, or NR;
Z is O or S;
Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-5 fluorine atoms and/or one —OC1-3 alkyl, said —OC1-3 alkyl being optionally substituted with 1-7 fluorine atoms; and
R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 Aryl, —OC1-6 alkyl, —OC2-6 alkenyl, —OC2-6 alkynyl, —OC6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, 5-6-membered Heteroaryl, —OC3-6 Cycloalkyl, —O 5-6-membered Heterocyclyl, —O 5-6 membered Heteroaryl, and a C1-4 alkyl group which comprises at a position interrupting the chain or at the end of the chain a group selected from C6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, and 5-6-membered Heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl is linear or branched and optionally substituted with 1-5 fluorine atoms and/or one —OCH3 or —OCF3 group, and each of said Aryl, Cycloalkyl, Heteroaryl, Heterocyclyl, —OAryl, —OCycloalkyl, —OHeteroaryl, and —OHeterocyclyl groups is optionally substituted with 1-7 halogen atoms and/or one —OCH3 or —OCF3 group.

### Claim 2 (depends on 1)

A compound having the formula I as recited in claim 1, wherein X is N and Y is O.

### Claim 3 (depends on 1)

A compound having the formula I as recited in claim 1, wherein X is N and Y is S.

### Claim 4 (depends on 1)

A compound having the formula I as recited in claim 1, wherein X is N and Y is NR.

### Claim 5 (depends on 1)

A compound having the formula I as recited in claim 1, wherein X is CR and Y is O.

### Claim 6 (depends on 1)

A compound having the formula I as recited in claim 1, wherein X is CR and Y is S.

### Claim 7 (depends on 1)

A compound having the formula I as recited in claim 1, wherein X is CR and Y is NR.

### Claim 8 (depends on 1)

A compound having formula I as recited in claim 1, wherein
R5 is selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, C2-5 alkynyl, OC1-5 alkyl, OC2-5 alkenyl, OC2-5 alkynyl, and phenyl, wherein said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl are optionally substituted with 1-5 fluorine atoms, and said phenyl is optionally substituted with 1-5 halogens.

### Claim 9 (depends on 1)

A compound as recited in claim 1, wherein
R1 and R2 are each H or C1-3 alkyl, where the number of carbon atoms in R1 and R2 together is 0-5;
R3 and R4 are each independently C1-5 alkyl;
R5 is selected from the group consisting of C1-5 alkyl and —OC1-5 alkyl, wherein said alkyl and —Oalkyl are optionally substituted with 1-5 fluorine atoms, and
Z is O.

### Claim 10 (depends on 9)

A compound as recited in claim 9, wherein R5 is C1-3 alkyl, —OC1-3 alkyl, CF3, C2F5, —OCF3 or —OC2F5; and
R3 and R4 are each n-propyl.

### Claim 11

A compound having Formula Ia
41
and pharmaceutically acceptable salts thereof, wherein
R1 and R2 are each independently selected from the group consisting of H, F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-3 halogen atoms; or optionally R1 and R2 together form a C3-6 cycloalkyl;
R3 and R4 are each independently selected from the group consisting of C1-C5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups may be linear or branched and are optionally substituted with 1-5 fluorine atoms;
X is N or CR;
Y is O, S, or NR;
Z is O or S;
Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-5 fluorine atoms and/or one —OC1-3 alkyl, said —OC1-3 alkyl being optionally substituted with 1-7 fluorine atoms;
R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 Aryl, —OC1-6 alkyl, —OC2-6 alkenyl, —OC6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, 5-6-membered Heteroaryl, —OC3-6 Cycloalkyl, —O 5-6-membered Heterocyclyl, —O 5-6 membered Heteroaryl, and a C1-4 alkyl group which comprises at a position interrupting the chain or at the end of the chain a group selected from C6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, and 5-6-membered Heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl is optionally substituted with 1-5 fluorine atoms and/or one —OCH3 or —OCF3 group, and each of said Aryl, Cycloalkyl, Heteroaryl, Heterocyclyl, —OAryl, —OCycloalkyl, —OHeteroaryl, and —OHeterocyclyl groups is optionally substituted with 1-7 halogen atoms and/or one —OCH3 or —OCF3 group; and
R6 is a group that is easily removed under physiological conditions during or after administration to a mammalian patient to yield a compound having Formula I, or the carboxylate anion thereof (in solution), or a pharmaceutically acceptable salt thereof.

### Claim 12

A compound having Formula Ia,
42
and pharmaceutically acceptable salts thereof, wherein
R1 and R2 are each independently selected from the group consisting of H, F, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-3 halogen atoms; or optionally R1 and R2 together form a C3-6 cycloalkyl;
R3 and R4 are each independently selected from the group consisting of C1-C5 alkyl, C2-5 alkenyl, C2-5 alkynyl, and chlorine, provided that R3 and R4 are not both chlorine, wherein said alkyl, alkenyl, and alkynyl groups may be linear or branched and are optionally substituted with 1-5 fluorine atoms;
X is N or CR;
Y is O, S, or NR;
Z is O or S;
Each R is independently selected from the group consisting of H, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkynyl, wherein said alkyl, alkenyl, and alkynyl may be linear or branched and are optionally substituted with 1-5 fluorine atoms and/or one —OC1-3 alkyl, said —OC1-3 alkyl being optionally substituted with 1-7 fluorine atoms;
R5 is selected from the group consisting of H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 Aryl, —OC1-6 alkyl, —OC2-6 alkenyl, —OC6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, 5-6-membered Heteroaryl, —OC3-6 Cycloalkyl, —O 5-6-membered Heterocyclyl, —O 5-6 membered Heteroaryl, and a C1-4 alkyl group which comprises at a position interrupting the chain or at the end of the chain a group selected from C6-10 Aryl, C3-6 Cycloalkyl, 5-6-membered Heterocyclyl, and 5-6-membered Heteroaryl, wherein each of said alkyl, alkenyl, alkynyl, —Oalkyl, —Oalkenyl, and —Oalkynyl is optionally substituted with 1-5 fluorine atoms and/or one —OCH3 or —OCF3 group, and each of said Aryl, Cycloalkyl, Heteroaryl, Heterocyclyl, —OAryl, —OCycloalkyl, —OHeteroaryl, and —OHeterocyclyl groups is optionally substituted with 1-7 halogen atoms and/or one —OCH3 or —OCF3 group;
R6 is selected from the group consisting of —OR7, —OCH2OR7, —OCH(CH3)OR7, —OCH2OC(O)R7, —OCH(CH3)OC(O)R7, —OCH2OC(O)OR7, —OCH(CH3)OC(O)OR7, —NR8R8, and —ONR8R8;
Each R7 is independently selected from C1-6 alkyl optionally substituted with one or two groups selected from —CO2H, —CONH2, —NH2, —OH, —OAc, NHAc, and phenyl; and
Each R8 is independently selected from H and R7.

### Claim 13

A compound represented by any of the structures of Examples 1-29, shown below:
2 Example 1 43 Example 2 44 Example 3 45 Example 4 46 Example 5 47 Example 6 48 Example 7 49 Example 8 50 51 Example R1 R2 R3 R4 R5 9 methyl methyl Cl propyl trifluoromethyl 10 ethyl H propyl propyl trifuoromethyl 11 ethyl methyl propyl propyl trifuoromethyl 12 propyl methyl propyl propyl trifluoromethyl 13 propyl H propyl propyl trifluoromethyl 14 propyl propyl propyl propyl trifluoromethyl 15 ethyl ethyl propyl propyl trifluoromethyl 16 methyl H Cl propyl ethyl 17 methyl methyl Cl propyl ethyl 18 methyl H Cl propyl trifluoromethyl 19 methyl methyl propyl propyl ethyl 20 methyl methyl propyl propyl methyl 21 methyl methyl propyl propyl methoxy 22 methyl H propyl propyl trifluoromethyl 23 methyl H propyl propyl phenyl 24 methyl methyl propyl propyl phenyl 25 methyl ethyl propyl propyl phenyl 26 H H propyl propyl trifluoromethyl 27 4-penten-1-yl H propyl propyl trifuoromethyl 28 cyclobutylidene propyl propyl trifuoromethyl 29 cyclohexylidene propyl propyl trifuoromethyl

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 12)

A pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A method for treating, controlling, or preventing non-insulin dependent (Type 2) diabetes mellitus in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 17 (depends on 1)

A method for treating, controlling or preventing hyperglycemia in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 18 (depends on 1)

A method for treating, controlling or preventing lipid disorders, hyperlipidemia, or low HDL in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 19 (depends on 1)

A method for treating, controlling or preventing obesity in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 20 (depends on 1)

A method for treating, controlling or preventing hypercholesterolemia in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 21 (depends on 1)

A method for treating, controlling or preventing hypertriglyceridemia in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 22 (depends on 1)

A method for treating, controlling or preventing dyslipidemia and/or low HDL cholesterol in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 23 (depends on 1)

A method for treating, controlling or preventing atherosclerosis in a mammalian patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 24 (depends on 1)

A method of treating, controlling or preventing one or more diseases, disorders, or conditions selected from the group consisting of (1) non-insulin dependent diabetes mellitus (NIDDM), (2) hyperglycemia, (3) low glucose tolerance, (4) insulin resistance, (5) obesity, (6) lipid disorders, (7) dyslipidemia, (8) hyperlipidemia, (9) hypertriglyceridemia, (10) hypercholesterolemia, (11) low HDL levels, (12) high LDL levels, (13) atherosclerosis and its sequelae, (14) vascular restenosis, (15) irritable bowel syndrome, (16) inflammatory bowel disease, including Crohn's disease and ulcerative colitis, (17) other inflammatory conditions, (18) pancreatitis, (19) abdominal obesity, (20) neurodegenerative disease, (21) retinopathy, (22) neoplastic conditions, (23) adipose cell tumors, (24) adipose cell carcinomas, such as liposarcoma, (25) prostate cancer and other cancers, including gastric, breast, bladder and colon cancers, (26) angiogenesis, (27) Alzheimer's disease, (28) psoriasis, (29) high blood pressure, (30) Syndrome X, (31) ovarian hyperandrogenism (polycystic ovarian syndrome), and other disorders where insulin resistance is a component, said method comprising the administration of an effective amount of a compound of claim 1.

### Claim 25 (depends on 1)

A method of treating, controlling or preventing one or more diseases, disorders, or conditions selected from the group consisting of (1) diabetes mellitus, and especially non-insulin dependent diabetes mellitus (NIDDM), (2) hyperglycemia, (3) low glucose tolerance, (4) insulin resistance, (5) obesity, (6) lipid disorders, (7) dyslipidemia, (8) hyperlipidemia, (9) hypertriglyceridemia, (10) hypercholesterolemia, (11) low HDL levels, (12) high LDL levels, (13) atherosclerosis and its sequelae, (14) vascular restenosis, (15) irritable bowel syndrome, (16) inflamatory bowel disease, including Crohn's disease and ulcerative colitis, (17) other inflammatory conditions, (18) pancreatitis, (19) abdominal obesity, (20) neurodegenerative disease, (21) retinopathy, (22) neoplastic conditions, (23) adipose cell tumors, (24) adipose cell carcinomas, such as liposarcoma, (25) prostate cancer and other cancers, including gastric, breast, bladder and colon cancers, (26) angiogenesis, (27) Alzheimer's disease, (28) psoriasis, (29) high blood pressure, (30) Syndrome X, (31) ovarian hyperandrogenism (polycystic ovarian syndrome), and other disorders where insulin resistance is a component, said method comprising the administration of an effective amount of a compound of claim 1, and an effective amount of one or more other compounds selected from the group consisting of:
(a) insulin sensitizers including (i) PPARγ agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, and the like), and compounds disclosed in WO97/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin; (iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors, and (iv) dipeptidyl peptidase IV (DP-IV) inhibitors;
(b) insulin or insulin mimetics;
(c) sulfonylureas such as tolbutamide and glipizide, or related materials;
(d) α-glucosidase inhibitors (such as acarbose);
(e) cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, itavastatin, ZD-4522 and other statins), (ii) sequestrants (cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (v) PPARα/γ dual agonists, such as KRP-297, (vi) inhibitors of cholesterol absorption, such as for example beta-sitosterol, (vii) acyl CoA:cholesterol acyltransferase inhibitors, such as for example avasimibe, and (viii) anti-oxidants, such as probucol;
(f) PPARδ agonists such as those disclosed in WO97/28149;
(g) antiobesity compounds such as fenfluramine, dexfenfluramine, phentiramine, sulbitramine, orlistat, neuropeptide Y5 inhibitors, and β3 adrenergic receptor agonists;
(h) an ileal bile acid transporter inhibitor; and
(i) agents intended for use in inflammatory conditions such as aspirin, non-steroidal anti-inflammatory drugs, glucocorticoids, azulfidine, and cyclooxygenase oxygenase 2 selective inhibitors.

### Claim 26 (depends on 1)

A method for the treatment, control, or prevention of one or more conditions selected from hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia, and dyslipidemia, which method comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound as recited in claim 1.

### Claim 27 (depends on 1, 26)

The method as recited in claim 26, wherein the compound of claim 1 is administered with an HMG-CoA reductase inhibitor.

### Claim 28 (depends on 27)

The method as recited in claim 27, wherein the HMG-CoA reductase inhibitor is a statin.

### Claim 29 (depends on 28)

The method as recited in claim 28, wherein the statin is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, ZD-4522 and rivastatin.

### Claim 30 (depends on 1)

A method for the treatment, control, or prevention of one or more conditions selected from inflammatory conditions, inflammatory bowel disease, Crohn's disease, and ulcerative colitis, which method comprises administering to a mammalian patient in need of such treatment a therapeutically effective amount of a compound as recited in claim 1.

### Claim 31 (depends on 1, 30)

The method as recited in claim 30, wherein the compound according to claim 1 is administered with an HMG-CoA reductase inhibitor.

### Claim 32 (depends on 31)

The method as recited in claim 31, wherein the HMG-CoA reductase inhibitor is a statin selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, itavastatin, ZD-4522 and rivastatin.

### Claim 33 (depends on 1)

A method for treating, preventing or controlling atherosclerosis in a mammalian patient in need of such treatment comprising the administration to said patient of an effective amount of a compound of claim 1 and an effective amount of an HMG-CoA reductase inhibitor.

### Claim 34 (depends on 1)

A pharmaceutical composition for the treatment, prevention or control of atherosclerosis, comprising: (1) a compound according to claim 1, (2) an HMG-CoA reductase inhibitor, and (3) a pharmaceutically acceptable carrier.

### Claim 35 (depends on 1)

A pharmaceutical composition comprising (1) a compound according to claim 1, (2) one or more compounds selected from the group consisting of:
(a) insulin sensitizers including (i) PPARγ agonists such as the glitazones (e.g. troglitazone, pioglitazone, englitazone, MCC-555, rosiglitazone, and the like), and compounds disclosed in WO97/27857, 97/28115, 97/28137 and 97/27847; (ii) biguanides such as metformin and phenformin; (iii) protein tyrosine phosphatase-1B (PTP-1B) inhibitors, and (iv) dipeptidyl peptidase IV (DP-IV) inhibitors;
(b) insulin or insulin mimetics;
(c) sulfonylureas such as tolbutamide and glipizide, or related materials;
(d) α-glucosidase inhibitors (such as acarbose);
(e) cholesterol lowering agents such as (i) HMG-CoA reductase inhibitors (lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rivastatin, itavastatin, ZD-4522 and other statins), (ii) sequestrants (cholestyramine, colestipol, and dialkylaminoalkyl derivatives of a cross-linked dextran), (iii) nicotinyl alcohol, nicotinic acid or a salt thereof, (iv) PPARα agonists such as fenofibric acid derivatives (gemfibrozil, clofibrate, fenofibrate and benzafibrate), (v) PPARα/γ dual agonists, such as KRP-297, (vi) inhibitors of cholesterol absorption, such as for example beta-sitosterol, (vii) acyl CoA:cholesterol acyltransferase inhibitors, such as for example avasimibe, and (viii) anti-oxidants, such as probucol;
(f) PPARδ agonists such as those disclosed in WO97/28149;
(g) antiobesity compounds such as fenfluramine, dexfenfluramine, phentiramine, sulbitramine, orlistat, neuropeptide Y5 inhibitors, and β3 adrenergic receptor agonists;
(h) an ileal bile acid transporter inhibitor; and
(i) agents intended for use in inflammatory conditions such as aspirin, non-steroidal anti-inflammatory drugs, glucocorticoids, azulfidine, and cycloooxygenase 2 selective inhibitors; and (3) a pharmaceutically acceptable carrier.
